Sangamo Biosciences (SGMO) Misses Q3 EPS by 2c

Sangamo Biosciences (NASDAQ: SGMO) reported Q3 EPS of ($0.27), $0.02 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $4.24 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Corpay agrees to $100M FTC settlement over marketing practices
• Lumentum shares rise on analyst upgrades, AI demand outlook